Updated:
Regeneron Pharmaceuticals
Schleifer and Yancopoulos built Regeneron into a biotech that created 9 approved drugs from its own labs, spending $4.4B on R&D in 2025.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals was founded in 1988 by Leonard Schleifer, a neurologist, and George Yancopoulos, an immunologist, who met while Schleifer was a professor and Yancopoulos a student at Columbia. The company’s original model of pairing elite scientific talent with an industrialized, proprietary discovery platform has produced a portfolio of treatments for eye diseases, inflammatory conditions, cancer, and rare diseases. Unlike traditional pharma conglomerates that rely heavily on acquisitions for pipeline growth, almost all of Regeneron’s approved medicines originated in its own laboratories. Regeneron deploys capital almost entirely through internal research and development, reporting $4.4 billion in R&D expense in 2025. Its therapeutic coverage spans ophthalmology with Eylea, immunology and allergy with Dupixent, oncology with Libtayo, and cardiovascular disease, among others. The company is expanding aggressively into genetic medicine, building on its Regeneron Genetics Center, which has sequenced over 3 million exomes to identify drug targets. Its financial model is rooted in high-margin co-development revenue — Dupixent, for example, is partnered with Sanofi — rather than a fund structure or outside LP commitments. Regeneron operates in more than 12 countries and conducts clinical trials in over 50. The firm employs more than 15,400 people globally, some 1,800 of whom hold MD or PhD degrees. It maintains major campuses in New York’s Hudson Valley, with additional offices in the UK, Ireland, and Japan. In 2024, Regeneron was named to the Dow Jones Sustainability World Index and topped Science magazine’s Top Employers list for the 11th time. Through its wholly owned Regeneron Genetics Center it operates what has become one of the world’s largest private genetic sequencing initiatives, linking genomic data with clinical outcomes. What structurally separates Regeneron from a classic asset gatherer is that it is a public, scientist-led pharmaceutical company that reinvests profits rather than charging management fees. Its governance is unusually stable — Schleifer and Yancopoulos have jointly led the firm for over three decades — and its scientific productivity has drawn comparisons to a permanent, self-funding venture fund focused on medicinal chemistry. The company also operates a distinct philanthropic vehicle, the Regeneron Science Talent Search, now in its second decade, which competes with the Intel/STS legacy program to identify high-school science talent.
General information
Firm type
Asset Manager
Year founded
1988
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Tarrytown
Corporate office
Tarrytown, NY, United States
Additional offices
Sleepy Hollow, NY · Rensselaer, NY · Uxbridge, UK · Dublin, Ireland · Tokyo, Japan
Principals
Leonard S. Schleifer
Co-Founder, President and Chief Executive Officer
George D. Yancopoulos
Co-Founder, President and Chief Scientific Officer
Sector focus
Frequently asked questions
Who makes the major capital-allocation decisions at Regeneron?
Capital allocation is driven by the co-founders: CEO Leonard Schleifer sets the strategic direction, while President and Chief Scientific Officer George Yancopoulos oversees the research pipeline. Major R&D and partnership commitments are authorized by the board, but the company’s science-forward posture means Yancopoulos’s team effectively decides which drug candidates advance.
How does Regeneron screen new drug candidates without a typical investor-led model?
Regeneron’s pipeline originates almost entirely from its own target-discovery work. The Regeneron Genetics Center has sequenced over 3 million exomes, linking genetic variants to disease phenotypes. Targets identified there are fed into the VelociSuite technology platform to produce fully human antibodies, a process that systematically generates candidates for clinical testing.
Does Regeneron function like a venture capital firm by spinning out portfolio companies?
No. It operates as a fully integrated pharmaceutical company. It does not raise outside funds, charge management fees, or syndicate risk through VC-style spinouts. Instead, it self-funds R&D from commercial revenues and co-development agreements, most notably the global partnership with Sanofi on Dupixent.
What therapeutic areas does Regeneron avoid?
Regeneron does not publicly declare strict sector exclusions. Its current pipeline focuses on eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, and infectious diseases. It has not disclosed active programs in areas such as reproductive health or consumer medical devices.
How is Regeneron’s substantial R&D budget distinct from the investment budgets of family offices or institutional allocators?
The $4.4 billion in 2025 R&D is operating expense for internal drug development, not deployed capital in an investment portfolio sense. Regeneron does not manage an external fund for LPs or charge a management fee. Its business is inventing and commercializing its own medicines, with risk shared through pharmaceutical partnerships rather than fund structures.
Does Regeneron manage philanthropic programs, and how are they structured?
Yes, its principal philanthropic initiative is the Regeneron Science Talent Search, which it has funded for over a decade. This program identifies and supports high-school science talent through scholarships and is run as a corporate social responsibility effort, separate from its drug-development operations.
What is Regeneron’s approach to co-investment alongside other pharma companies?
Regeneron collaborates extensively. Its flagship partnership is with Sanofi on Dupixent and oncology programs, structured as a profit-sharing co-development deal. It also has joint ventures, such as with Bayer on Eylea. These are scientific and commercial alliances, not passive institutional co-investments, and they typically involve shared development costs and split revenues.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: